144 related articles for article (PubMed ID: 8863629)
21. Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status.
Maas S; Warskulat U; Steinhoff C; Mueller W; Grimm MO; Schulz WA; Seifert HH
Urology; 2004 Feb; 63(2):392-7. PubMed ID: 14972509
[TBL] [Abstract][Full Text] [Related]
22. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy.
Zlotta AR; Noel JC; Fayt I; Drowart A; Van Vooren JP; Huygen K; Simon J; Schulman CC
J Urol; 1999 Mar; 161(3):792-8. PubMed ID: 10022686
[TBL] [Abstract][Full Text] [Related]
23. Expression of p53 and pRb in bladder and prostate cancers of patients having both cancers.
Singh A; Jones RF; Friedman H; Hathir S; Soos G; Zabo A; Haas GP
Anticancer Res; 1999; 19(6B):5415-7. PubMed ID: 10697570
[TBL] [Abstract][Full Text] [Related]
24. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma.
Chatterjee SJ; Datar R; Youssefzadeh D; George B; Goebell PJ; Stein JP; Young L; Shi SR; Gee C; Groshen S; Skinner DG; Cote RJ
J Clin Oncol; 2004 Mar; 22(6):1007-13. PubMed ID: 14981105
[TBL] [Abstract][Full Text] [Related]
25. P53 mutation predicts intravesical adriamycin instillation failure in superficial transitional cell carcinoma of bladder.
Shiraishi K; Eguchi S; Mohri J; Kamiryo Y
Anticancer Res; 2003; 23(4):3475-8. PubMed ID: 12926093
[TBL] [Abstract][Full Text] [Related]
26. Expression of bcl-2 and bcl-X in bladder cancer.
Kirsh EJ; Baunoch DA; Stadler WM
J Urol; 1998 Apr; 159(4):1348-53. PubMed ID: 9507882
[TBL] [Abstract][Full Text] [Related]
27. Expression of vascular endothelial growth factor, receptor KDR and p53 protein in transitional cell carcinoma of the bladder.
Liu L; Zhu D; Gao R; Guo H
Urol Int; 2008; 81(1):72-6. PubMed ID: 18645275
[TBL] [Abstract][Full Text] [Related]
28. Analysis of genetic events in 17p13 and 9p21 regions supports predominant monoclonal origin of multifocal and recurrent bladder cancer.
Trkova M; Babjuk M; Duskova J; Benesova-Minarikova L; Soukup V; Mares J; Minarik M; Sedlacek Z
Cancer Lett; 2006 Oct; 242(1):68-76. PubMed ID: 16343743
[TBL] [Abstract][Full Text] [Related]
29. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer.
Shariat SF; Tokunaga H; Zhou J; Kim J; Ayala GE; Benedict WF; Lerner SP
J Clin Oncol; 2004 Mar; 22(6):1014-24. PubMed ID: 14981102
[TBL] [Abstract][Full Text] [Related]
30. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53.
Cote RJ; Dunn MD; Chatterjee SJ; Stein JP; Shi SR; Tran QC; Hu SX; Xu HJ; Groshen S; Taylor CR; Skinner DG; Benedict WF
Cancer Res; 1998 Mar; 58(6):1090-4. PubMed ID: 9515785
[TBL] [Abstract][Full Text] [Related]
31. [The p53 positivity in non-tumor mucosa in patients with superficial urinary bladder cancer].
Soukup V; Babjuk M; Dusková J; Pesl M; Szakácsova M; Zámefnik L; Dvorácek J
Cas Lek Cesk; 2007; 146(1):63-7. PubMed ID: 17310587
[TBL] [Abstract][Full Text] [Related]
32. Loss of p21Waf1 expression is a strong predictor of reduced survival in primary superficial bladder cancers.
Migaldi M; Sgambato A; Garagnani L; Ardito R; Ferrari P; De Gaetani C; Cittadini A; Trentini GP
Clin Cancer Res; 2000 Aug; 6(8):3131-8. PubMed ID: 10955794
[TBL] [Abstract][Full Text] [Related]
33. Grade progression and regression in recurrent urothelial cancer.
Borhan A; Reeder JE; O'Connell MJ; Wright KO; Wheeless LL; di Sant'Agnese PA; McNally ML; Messing EM
J Urol; 2003 Jun; 169(6):2106-9. PubMed ID: 12771728
[TBL] [Abstract][Full Text] [Related]
34. Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha.
Esuvaranathan K; Chiong E; Thamboo TP; Chan YH; Kamaraj R; Mahendran R; Teh M
Cancer; 2007 Mar; 109(6):1097-105. PubMed ID: 17311305
[TBL] [Abstract][Full Text] [Related]
35. P53 accumulation, deoxyribonucleic acid ploidy and progression of bladder cancer.
Raitanen MP; Tammela TL; Kallioinen M; Isola J
J Urol; 1997 Apr; 157(4):1250-3. PubMed ID: 9120913
[TBL] [Abstract][Full Text] [Related]
36. The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder.
Popov Z; Hoznek A; Colombel M; Bastuji-Garin S; Lefrere-Belda MA; Bellot J; Abboh CC; Mazerolles C; Chopin DK
Cancer; 1997 Oct; 80(8):1472-81. PubMed ID: 9338472
[TBL] [Abstract][Full Text] [Related]
37. Abnormal bcl-2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer.
Pollack A; Wu CS; Czerniak B; Zagars GK; Benedict WF; McDonnell TJ
Clin Cancer Res; 1997 Oct; 3(10):1823-9. PubMed ID: 9815569
[TBL] [Abstract][Full Text] [Related]
38. Does the expression of fascin-1 and tumor subclassification help to assess the risk of recurrence and progression in t1 urothelial urinary bladder carcinoma?
Soukup V; Babjuk M; Dusková J; Pesl M; Szakáczová M; Zámecník L; Dvorácek J
Urol Int; 2008; 80(4):413-8. PubMed ID: 18587253
[TBL] [Abstract][Full Text] [Related]
39. Protein expression and gene copy number analysis of topoisomerase 2alpha, HER2 and P53 in minimally invasive urothelial carcinoma of the urinary bladder--a multitissue array study with prognostic implications.
Krüger S; Lange I; Kausch I; Feller AC
Anticancer Res; 2005; 25(1A):263-71. PubMed ID: 15816547
[TBL] [Abstract][Full Text] [Related]
40. p53 nuclear accumulation is not associated with decreased disease-free survival in patients with node positive transitional cell carcinoma of the bladder.
Fleshner N; Kapusta L; Ezer D; Herschorn S; Klotz L
J Urol; 2000 Oct; 164(4):1177-82. PubMed ID: 10992361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
